Drug Type Small molecule drug |
Synonyms (1-hydroxy-ethylidene)diphosphonic acid, (1-Hydroxyethylene)diphosphonic acid, (1-Hydroxyethylidene)bis(phosphonic acid) + [35] |
Target |
Action inhibitors |
Mechanism Bone resorption factor inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (01 Sep 1977), |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC2H8Na2O7P2 |
InChIKeyFCBYKAIUKRZZGW-UHFFFAOYSA-N |
CAS Registry7414-83-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00314 | Etidronate Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ossification, Heterotopic | Japan | 28 Sep 1990 | |
Osteoporosis | United States | 01 Sep 1977 | |
Osteitis Deformans | United States | 01 Sep 1977 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pseudoxanthoma Elasticum | Phase 3 | Netherlands | 26 Apr 2023 | |
Fahr's Disease | Phase 2 | Netherlands | 03 Apr 2023 | |
HEM Dysplasia | Phase 2 | Netherlands | 03 Apr 2023 | |
ABCC6 deficiency | Preclinical | European Union | 11 Oct 2022 |
Phase 2 | 7 | MRI Scan+Etidronate | ifzdiznvhm(ntlkprobty) = jawsidpchz zqtaehwpmh (yswlbkergd, sgusdgaibi - rcucoagtyd) View more | - | 04 Oct 2022 | ||
Not Applicable | 49 | (Responders) | oxseqfejjj(hixvovehna) = hobplfeanj rtqftlefuc (wmipmsvoud, 1.5) View more | Positive | 27 Jul 2018 | ||
(Nonresponders) | oxseqfejjj(hixvovehna) = eaiqjqcmog rtqftlefuc (wmipmsvoud, 1.5) View more | ||||||
Not Applicable | Chronic glomerulonephritis | Glucocorticoid-induced osteoporosis N-terminal telopeptide of type I collagen (NTx) | uncarboxylated osteocalcin (ucOC) | 43 | nbkejvqzle(xvsflbrbtp) = There were no significant differences in BMD between these groups during the study pkzmzmgxkc (rtebwxapyu ) | Positive | 05 Nov 2013 | ||